Medicus Pharma begins Phase 2 clinical study in UAE to treat BCC

Medicus Pharma (NASDAQ:MDCX) has commenced patient recruitment for its Phase 2 SKNJCT-004 clinical study in the UAE, evaluating a non-invasive treatment for Basal Cell Carcinoma (BCC) with an aim to randomize 36 patients. This expansion follows progress in its US-based SKNJCT-003 study, which has already randomized over 75% of 90 participants and targets a potential market exceeding $2 billion, having shown over 60% clinical clearance in preliminary interim analysis. The company positions this as a significant step towards commercializing a novel, first-in-class non-invasive BCC treatment.

Analysis

Medicus Pharma (NASDAQ:MDCX) is advancing its clinical development program for a non-invasive Basal Cell Carcinoma (BCC) treatment by initiating a new Phase 2 study, SKNJCT-004, in the United Arab Emirates. This 36-patient trial will evaluate two dose levels of its drug candidate, D-MNA, against a placebo, expanding the company's clinical footprint internationally. This development runs in parallel with its ongoing AI-powered SKNJCT-003 Phase 2 study in the United States, which has already achieved over 75% randomization of its 90-patient target. The US study provided a significant positive signal in a March 2025 interim analysis, which demonstrated a preliminary clinical clearance rate of over 60%. While the company appropriately cautions that these interim results may not reflect the final outcome, this progress supports the CEO's assertion of a potential market opportunity exceeding $2 billion. The dual-trial strategy signifies a confident and accelerated approach toward commercializing what could be a first-in-class, non-invasive alternative to current BCC treatments.

Key Decisions for Investors

• Investors should view the commencement of a second Phase 2 trial in the UAE as a positive step that de-risks the clinical timeline and expands the potential patient data pool for its lead BCC asset.
• The preliminary interim analysis from the US study, showing over 60% clinical clearance, provides an early but strong indicator of efficacy, warranting close attention to the final data readout as a primary stock catalyst.
• Despite positive momentum, it is crucial to monitor for the completion of patient randomization in both studies and to factor in the inherent risk that the final results of the SKNJCT-003 trial may differ from the promising preliminary findings.